Lupin支付90M美元,解决与Astallas的专利纠纷,确保美国销售通用Mirabegron至2027年。 Lupin pays $90M to settle patent dispute with Astellas, securing U.S. sales of generic Mirabegron through 2027.

Lupin已经解决了与Astallas Pharma就其通用的Mirabegron专利争端,在2027年9月之前支付9 000万至7 500万美元的预付和每单位费用,以便继续在美国销售该药物。 Lupin has settled a patent dispute with Astellas Pharma over its generic Mirabegron, paying $90 million—$75 million upfront and per-unit fees through September 2027—to continue selling the drug in the U.S. 该协议解决了在2025年法院裁决后威胁到产品市场供应的诉讼。 The agreement resolves litigation that threatened the product’s market availability after a 2025 court ruling. Astallas确认了这一解决办法,它消除了Lupin的法律不确定性,并可能推迟其他通用竞争者进入,使Lupin和Zydus生命科学公司受益。 Astellas confirmed the settlement, which removes legal uncertainty for Lupin and may delay entry by other generic competitors, benefiting Lupin and Zydus Lifesciences. 花旗分析师说,这笔交易有助于市场稳定和持续销售。 Citi analysts said the deal supports market stability and continued sales.